CN104042586A - Paroxetine enteric-coated and sustained-release tablet and preparation method thereof - Google Patents
Paroxetine enteric-coated and sustained-release tablet and preparation method thereof Download PDFInfo
- Publication number
- CN104042586A CN104042586A CN201410267492.0A CN201410267492A CN104042586A CN 104042586 A CN104042586 A CN 104042586A CN 201410267492 A CN201410267492 A CN 201410267492A CN 104042586 A CN104042586 A CN 104042586A
- Authority
- CN
- China
- Prior art keywords
- enteric
- paroxetine
- sustained
- release
- antiplastering aid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a paroxetine enteric-coated and sustained-release tablet, which comprises a single-layer tablet core, a sustained-release coating film and an enteric coating film, wherein the single-layer tablet core contains paroxetine or pharmaceutically acceptable salt and a sustained-release skeleton material; and the invention further provides a preparation method of the paroxetine enteric-coated and sustained-release tablet. The paroxetine enteric-coated and sustained-release tablet is simple in production technology and stable in quality.
Description
Technical field
The present invention relates to field of pharmaceutical preparations, be specifically related to paroxetine enteric sustained-release sheet and preparation method thereof.
Background technology
Paroxetine (Paroxetine) is phenylpiperidine derivative, is that a kind of selectivity 5-hydroxy tryptamine (5-HT) absorbs blocade (SSRIs) again, the clinical Cure of depression that is widely used in.According to relevant investigation, show, at the about 3%-5% of China's depression rate, had at present 2,600 ten thousand people of surpassing to suffer from depression.Along with social development, live in the metropolitan white collars such as Beijing, Shanghai and Guangzhou and under the environment of the high competition of high pressure, become rapidly for this reason sick group of people at high risk.
Paroxetine (C19H20FNO3) chemistry (-)-(3S, 4S)-4-(4-fluorophenyl)-3-[[3 by name, 4-(sub-methoxyl group) phenoxy group] methyl] piperidines.There is following chemical structural formula:
In medicine, paroxetine exists with forms such as hydrochlorate semihydrate or hydrochlorate anhydrides conventionally.
Paroxetine enteric sustained-release sheet is by the exploitation of GlaxoSmithKline PLC (GSK) company, with trade name Paxil
list marketing, the clinical major depressive disorder that is used for the treatment of, Panic disorder (with or without agoraphobia), social anxiety disorder and premenstrual dysphoric disease etc.Enteric-coated sustained-release tablet can prevent that medicine is in gastric decomposition failure and the stimulation to stomach, and controls medicine and at intestinal, slowly and steadily discharge etc.Compare with common fast dissolving dosage form, this dosage form can make human body obtain and treat stably blood drug level, and reduces gastrointestinal side effect.
US5422123A discloses the double-layer tablet slow-released system being comprised of pastille hydrophilic matrix layer and bearing bed.CN1117567C discloses coating and the controlled release double-layer tablet of carrying out pH sensitivity on hydrophilic matrix label.Paroxetine slow release micropills preparation is disclosed in CN101143136A.A kind of time delay and slow releasing composition that comprises the paroxetine of pastille micropill, slow release layer, sealing coat and enteric layer disclosed in CN101371836A.
The paroxetine enteric sustained-release preparation that above prior art provides has adopted many particle systems and the double-layer tablet technique of more complicated, is unfavorable for reducing production costs and drug price, also makes the quality control of medicine have larger difficulty and risk.Therefore be still necessary to provide a kind of more simple paroxetine enteric sustained-release preparation.
Summary of the invention
The invention provides a kind of paroxetine enteric sustained-release sheet, comprise the monolayer label that contains paroxetine or its pharmaceutically acceptable salt and slow release framework material, extended release coatings film, enteric coating film.
According to the present invention, paroxetine or its pharmaceutically acceptable salt be hydrochlorate semihydrate and hydrochlorate without hydrate, described paroxetine or its pharmaceutically acceptable salt are through grinding or micronized, particle diameter D50≤60 μ m, D90≤150 μ m; Be preferably D50≤50 μ m, D90≤130 μ m.Wherein D90 represents that in diameter of particle cumulative distribution, accumulated value is 90% corresponding particle diameter, and in like manner D50 represents that in cumulative distribution, accumulated value is 50% corresponding particle diameter.
According to the present invention, the paroxetine enteric sustained-release sheet of single dosage contains active component counts 1mg-50mg by paroxetine, is preferably 10mg-40mg, particularly 12.5mg, 25mg and 37.5mg.
According to the present invention, sustained-release matrix material is selected from high viscosity hypromellose, described high viscosity refers at 20 ℃ and measures, the hypromellose solution viscosity of 2% (w/v) is not less than 80mPas, and common high viscosity hypromellose is as hypromellose K100LV, HPMC K4M/K4M CR, hypromellose K15M, hypromellose K100M, hypromellose E4M, hypromellose E10M.It is 10%-25% that the consumption of sustained-release matrix material accounts for whole label weight ratio, preferably 15%-25%.
According to the present invention, comprise that the monolayer label that contains paroxetine or its pharmaceutically acceptable salt and slow release framework material can also contain pharmaceutically acceptable additive, comprises filler, binding agent, lubricant etc.Wherein said filler can be selected from lactose, microcrystalline Cellulose, mannitol, calcium hydrogen phosphate (two water or anhydrous), calcium sulfate, calcium carbonate, starch, pregelatinized Starch, be preferably one or more in microcrystalline Cellulose, lactose, calcium hydrogen phosphate (two water or anhydrous), the weight ratio that the consumption of filler accounts for monolayer label is 40%～75%, binding agent can be selected from low viscosity hypromellose, polyvidone, copolyvidone, hydroxypropyl cellulose, gelatin, methylcellulose, starch, Lac, sodium carboxymethyl cellulose, tragcanth, sodium alginate, carbomer, polyvinyl alcohol, preferred low viscosity hypromellose, polyvidone, one or more in hydroxypropyl cellulose, the weight ratio that the consumption of binding agent accounts for monolayer label is 1%-6%, preferred 1%-4%, described low viscosity hypromellose refers at 20 ℃ and measures, the hypromellose solution viscosity of 2% (w/w) is no more than 20mPas, lubricant can be selected from one or more in magnesium stearate, stearic acid, sodium stearyl fumarate, castor oil hydrogenated, hydrogenated vegetable oil, polyethylene glycol 6000, Pulvis Talci, colloidal silica, silicon dioxide, and it is 1%-3% that lubricant quantity accounts for monolayer label weight ratio.
According to the present invention, extended release coatings film contains slow release filmogen, antiplastering aid.Wherein slow release filmogen is selected from ethyl cellulose, crylic acid resin, preferred acrylic resins class, and more preferably EUDRAGIT NE 30 D EUDRAGIT NE 30D, as strange NE30D especially.Antiplastering aid can be selected from Pulvis Talci, stearic acid, magnesium stearate, dibutyl sebacate, glyceryl monostearate, preferred ultra-fine other Pulvis Talci of level, its particle diameter D90≤10 μ m, preferably D90≤5 μ m; The ratio of slow release filmogen and antiplastering aid is 1: 1～1: 3 (w/w).
According to the present invention, extended release coatings film is counted 4%-9% with respect to the coating weightening finish of monolayer label by slow release filmogen, is more preferably 5%-7%.
According to the present invention, enteric coating film contains enteric material, antiplastering aid, plasticizer.Wherein enteric material is selected from crylic acid resin, preferable methyl acrylic copolymer C type (that is, EUDRAGIT L100-55), and it is as by name in commodity that common commercial methacrylic acid copolymer C type comprises
deng, wherein
aqueous dispersion for solid content 30%; Antiplastering aid is selected from the antiplastering aid of extended release coatings film, preferred ultra-fine other Pulvis Talci of level, the 18%-35% that antiplastering aid consumption is enteric material, preferably 20%-30%; Plasticizer is selected from Polyethylene Glycol, glyceryl triacetate, triethyl citrate, diethyl phthalate, dibutyl phthalate, optimization citric acid triethyl, the 7%-18% that plasticizer consumption is enteric material, preferably 10%-15%.
According to the present invention, enteric coating film is counted 4%-10% with respect to the coating weightening finish of having wrapped the slice, thin piece of extended release coatings by enteric material, preferably 5%-8%.
According to the present invention, enteric coating film is outer can carry out the common stomach dissolution type film coating of one deck again, as blocks happy Kanggong department
series coating powder, to improve slice, thin piece outward appearance, strengthens patient's identification ability.
More specifically, the invention provides a kind of paroxetine enteric sustained-release sheet, comprise the monolayer label that contains paroxetine or its pharmaceutically acceptable salt and slow release framework material, extended release coatings film, enteric coating film; It is characterized in that:
1) monolayer label contains with paroxetine and counts 10mg-40mg paroxetine or pharmaceutically acceptable salt, with the sustained-release matrix material that is equivalent to monolayer label gross weight 15%-25%, the filler of 40%-75%, the binding agent of 1%-4%, the lubricant of 1%-3%;
2) extended release coatings film contains slow release filmogen, antiplastering aid, and both ratios are 1: 1～1: 3 (w/w), and the coating weightening finish of extended release coatings film is counted 4%-9% by slow release filmogen, preferably 5%-7%;
3) enteric coating film contains enteric material, antiplastering aid, plasticizer, the 20%-30% that wherein antiplastering aid consumption is enteric material, plasticizer consumption is the 10%-15% of enteric material, and the coating weightening finish of enteric coating film is counted 4%-10% by enteric material, preferably 5%-8%.
Further, the invention provides a kind of paroxetine enteric sustained-release sheet, comprise the monolayer label that contains paroxetine or its pharmaceutically acceptable salt and slow release framework material, extended release coatings film, enteric coating film; It is characterized in that:
1) monolayer label contains paroxetine hydrochloride or its hydrate of counting 10-40mg with paroxetine, with the high viscosity hypromellose that is equivalent to label gross weight 15%-25%, the lactose of 45%-75%, the low viscosity hypromellose of 1%-3%, the magnesium stearate that total amount is 1%-3% and silicon dioxide;
2) extended release coatings film contains slow release filmogen EUDRAGIT NE 30 D EUDRAGIT NE 30D, and antiplastering aid Pulvis Talci, and both ratios are 1: 1～1: 3 (w/w), and the coating weightening finish of extended release coatings film is counted 4%-9% by slow release filmogen;
3) enteric coating film contains enteric material EUDRAGIT L100-55, antiplastering aid Pulvis Talci, plasticizer triethyl citrate, the 20%-30% that wherein antiplastering aid consumption is enteric material, plasticizer consumption is the 10%-15% of enteric material, and the coating weightening finish of enteric coating film is counted 5%-8% by enteric material.
The present invention also provides the preparation method of described paroxetine enteric sustained-release sheet, comprises and prepares monolayer label, bag extended release coatings film, the processes such as enteric coated film.
Wherein the preparation process of monolayer label comprises the steps:
1) paroxetine or its pharmaceutically acceptable salt are mixed homogeneously with sustained-release matrix material, other pharmaceutically acceptable additives;
2) add the ethanol water of ethanol water or binding agent to granulate;
3) fluid bed drying;
4) optionally add extra sustained-release matrix material and other pharmaceutically acceptable additives, mix homogeneously;
5) by step mixed material compacting 4. in flakes.
Wherein in ethanol water, the ratio of ethanol and water is 4: 1 to 9: 1 (w/w), is preferably 5: 1 to 7: 1 (w/w).
Sustained release coating step is as follows:
1) after antiplastering aid (as Pulvis Talci) is uniformly dispersed in water, add slow release filmogen, continue to stir, form sustained release coating liquid.
2) label is placed in to coating pan, after homogeneous heating, with sustained release coating liquid, carries out sustained release coating.Sustained release coating stops hydrojet after reaching target weightening finish, dry.
Enteric coating step is as follows:
1) after antiplastering aid is uniformly dispersed in water, add plasticizer, stir, then add enteric material, form enteric coating liquid.
2) label after sustained release coating is placed in to coating pan, after homogeneous heating, by enteric coating liquid, carries out sustained release coating.Enteric coating stops hydrojet after reaching target weightening finish, dry.
For improving outward appearance, can optionally carry out at the outermost of slice, thin piece the stomach dissolution type film coating of different colours.
The specific embodiment
Below in conjunction with embodiment, the present invention will be further described, but the present invention is not subject to the restriction of embodiment.
Embodiment 1-3
The particle diameter of paroxetine hydrochloride semihydrate is D90=125 μ m, D50=45 μ m.14.22mg paroxetine hydrochloride semihydrate is equivalent to 12.5mg paroxetine, and other specifications by that analogy.
In prescription, especially very NE30D and L30D-55 are aqueous dispersion, and solid content is 30%, and in prescription, 24.0 (7.2) represent
consumption 24.0mg, wherein amount of solid is 7.2mg.
Label preparation method:
Active component, filler, slow-release material, binding agent mix homogeneously, the alcohol-water solution of (w/w) is granulated to add 5.8: 1, through fluid bed drying, adds colloidal silica after granulate, magnesium stearate is mixed, tabletting.
Sustained release coating:
100g Pulvis Talci (D90=3.8 μ m) is dispersed in 366.2g purified water, after stirring, adds 333.3g's
after continuing to stir, above-mentioned label is carried out to coating.
Enteric coating:
45g Pulvis Talci (D90=3.8 μ m) is dispersed in 552g purified water, after stirring, adds 18g triethyl citrate, continue to stir.Above-mentioned suspension is joined to 600g
in, after stirring, carry out coating.
With same or similar technical process Preparation Example 4-12.
Embodiment 4-5
Embodiment 6
Embodiment 7-9
Embodiment 10
Embodiment 11
Embodiment 12
Claims (10)
1. a paroxetine enteric sustained-release sheet, comprises the monolayer label that contains paroxetine or its pharmaceutically acceptable salt and slow release framework material, extended release coatings film, enteric coating film.
2. paroxetine enteric sustained-release sheet as claimed in claim 1, is characterized in that sustained-release matrix material is selected from high viscosity hypromellose, and sustained-release matrix material usage accounts for the 10%-25% of monolayer label gross weight.
3. paroxetine enteric sustained-release sheet as claimed in claim 1, is characterized in that extended release coatings film contains slow release filmogen and antiplastering aid, and both ratios are 1: 1～1: 3 (w/w).
4. paroxetine enteric sustained-release sheet as claimed in claim 3, is characterized in that slow release filmogen is selected from ethyl cellulose, crylic acid resin.
5. paroxetine enteric sustained-release sheet as claimed in claim 1, is characterized in that enteric coating film contains enteric material, antiplastering aid, plasticizer, the 18%-35% that wherein antiplastering aid consumption is enteric material, the 7%-18% that plasticizer consumption is enteric material.
6. paroxetine enteric sustained-release sheet as claimed in claim 5, is characterized in that enteric material is selected from crylic acid resin.
7. the paroxetine enteric sustained-release sheet as described in claim 3 or 5, is characterized in that antiplastering aid is selected from Pulvis Talci, stearic acid, magnesium stearate, dibutyl sebacate, glyceryl monostearate.
8. paroxetine enteric sustained-release sheet as claimed in claim 5, is characterized in that plasticizer is selected from Polyethylene Glycol, glyceryl triacetate, triethyl citrate, diethyl phthalate, dibutyl phthalate.
9. a paroxetine enteric sustained-release sheet, comprises the monolayer label that contains paroxetine or its pharmaceutically acceptable salt and slow release framework material, extended release coatings film, enteric coating film; It is characterized in that:
1) monolayer label contains with paroxetine and counts 10mg-40mg paroxetine or pharmaceutically acceptable salt, with the sustained-release matrix material that is equivalent to monolayer label gross weight 15%-25%, the filler of 40%-75%, the binding agent of 1%-4%, the lubricant of 1%-3%;
2) extended release coatings film contains slow release filmogen, antiplastering aid, and both ratios are 1: 1～1: 3 (w/w), and the coating weightening finish of extended release coatings film is counted 4%-9% by slow release filmogen;
3) enteric coating film contains enteric material, antiplastering aid, plasticizer, the 20%-30% that wherein antiplastering aid consumption is enteric material, and the 10%-15% that plasticizer consumption is enteric material, the coating weightening finish of enteric coating film is counted 4%-10% by enteric material.
10. a paroxetine enteric sustained-release sheet, comprises the monolayer label that contains paroxetine or its pharmaceutically acceptable salt and slow release framework material, extended release coatings film, enteric coating film; It is characterized in that:
1) monolayer label contains paroxetine hydrochloride or its hydrate of counting 10mg-40mg with paroxetine, with the high viscosity hypromellose that is equivalent to label gross weight 15%-25%, the lactose of 45%-75%, the low viscosity hypromellose of 1%-3%, the magnesium stearate that total amount is 1%-3% and silicon dioxide;
2) extended release coatings film contains slow release filmogen EUDRAGIT NE 30 D EUDRAGIT NE 30D, and antiplastering aid Pulvis Talci, and both ratios are 1: 1～1: 3 (w/w), and the coating weightening finish of extended release coatings film is counted 4%-9% by slow release filmogen;
3) enteric coating film contains enteric material EUDRAGIT L100-55, antiplastering aid Pulvis Talci, plasticizer triethyl citrate, the 20%-30% that wherein antiplastering aid consumption is enteric material, plasticizer consumption is the 10%-15% of enteric material, and the coating weightening finish of enteric coating film is counted 5%-8% by enteric material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410267492.0A CN104042586A (en) | 2014-06-08 | 2014-06-08 | Paroxetine enteric-coated and sustained-release tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410267492.0A CN104042586A (en) | 2014-06-08 | 2014-06-08 | Paroxetine enteric-coated and sustained-release tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104042586A true CN104042586A (en) | 2014-09-17 |
Family
ID=51496317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410267492.0A Pending CN104042586A (en) | 2014-06-08 | 2014-06-08 | Paroxetine enteric-coated and sustained-release tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104042586A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840445A (en) * | 2015-04-30 | 2015-08-19 | 南通市康桥油脂有限公司 | Paroxetine sustained release preparation and preparation method thereof |
| CN104940156A (en) * | 2015-06-09 | 2015-09-30 | 扬子江药业集团南京海陵药业有限公司 | Epalrestat enteric-coated and sustained-release tablets and preparation method thereof |
| CN105663074A (en) * | 2014-11-19 | 2016-06-15 | 广州玻思韬控释药业有限公司 | Enteric-coated sustained release tablet of serotonin reuptake inhibitor and preparation method of enteric-coated sustained release tablet |
| CN107307429A (en) * | 2017-07-04 | 2017-11-03 | 北京英茂药业有限公司 | Film coating pre-mix dose of probiotics preparation and preparation method thereof, application |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007052877A1 (en) * | 2005-11-04 | 2007-05-10 | Gl Pharmtech Corp. | An enteric sustained-release tablet comprising paroxetine |
| WO2007132344A2 (en) * | 2006-05-09 | 2007-11-22 | Aurobindo Pharma Limited | Controlled release compositions of an antidepressant agent |
| CN101143136A (en) * | 2006-09-13 | 2008-03-19 | 广东中大南海海洋生物技术工程中心有限公司 | Paroxetine slow release micropills preparation |
| CN101371836A (en) * | 2007-08-23 | 2009-02-25 | 珠海天翼医药技术开发有限公司 | Paroxetine enteric sustained-release composition |
| CN102670548A (en) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | Paroxetine hydrochloride osmotic pump type enteric controlled release tablet |
| WO2012123922A1 (en) * | 2011-03-17 | 2012-09-20 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| CN103550182A (en) * | 2013-10-29 | 2014-02-05 | 吉林省东盟制药有限公司 | Enteric-coated sustained release composition |
-
2014
- 2014-06-08 CN CN201410267492.0A patent/CN104042586A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007052877A1 (en) * | 2005-11-04 | 2007-05-10 | Gl Pharmtech Corp. | An enteric sustained-release tablet comprising paroxetine |
| WO2007132344A2 (en) * | 2006-05-09 | 2007-11-22 | Aurobindo Pharma Limited | Controlled release compositions of an antidepressant agent |
| CN101143136A (en) * | 2006-09-13 | 2008-03-19 | 广东中大南海海洋生物技术工程中心有限公司 | Paroxetine slow release micropills preparation |
| CN101371836A (en) * | 2007-08-23 | 2009-02-25 | 珠海天翼医药技术开发有限公司 | Paroxetine enteric sustained-release composition |
| CN102670548A (en) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | Paroxetine hydrochloride osmotic pump type enteric controlled release tablet |
| WO2012123922A1 (en) * | 2011-03-17 | 2012-09-20 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| CN103550182A (en) * | 2013-10-29 | 2014-02-05 | 吉林省东盟制药有限公司 | Enteric-coated sustained release composition |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663074A (en) * | 2014-11-19 | 2016-06-15 | 广州玻思韬控释药业有限公司 | Enteric-coated sustained release tablet of serotonin reuptake inhibitor and preparation method of enteric-coated sustained release tablet |
| CN104840445A (en) * | 2015-04-30 | 2015-08-19 | 南通市康桥油脂有限公司 | Paroxetine sustained release preparation and preparation method thereof |
| CN104840445B (en) * | 2015-04-30 | 2017-11-21 | 南通市康桥油脂有限公司 | A kind of paroxetine slow release preparation and preparation method thereof |
| CN104940156A (en) * | 2015-06-09 | 2015-09-30 | 扬子江药业集团南京海陵药业有限公司 | Epalrestat enteric-coated and sustained-release tablets and preparation method thereof |
| CN104940156B (en) * | 2015-06-09 | 2018-06-12 | 扬子江药业集团南京海陵药业有限公司 | Epalrestat enteric-coated sustained-release tablet and preparation method thereof |
| CN107307429A (en) * | 2017-07-04 | 2017-11-03 | 北京英茂药业有限公司 | Film coating pre-mix dose of probiotics preparation and preparation method thereof, application |
| CN107307429B (en) * | 2017-07-04 | 2020-09-22 | 北京英茂药业有限公司 | Film coating premix of probiotic preparation and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6588915B2 (en) | Pharmaceutical composition comprising AZD9291 | |
| TW550090B (en) | Stable oral pharmaceutical dosage forms for acid-unstable drug | |
| CN104220068B (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| JP5787882B2 (en) | Enteric tablets | |
| WO2013054872A1 (en) | TABLET INCLUDING 7-[4-(4-BENZO[ｂ]THIOPHEN-4-YL-PIPERAZIN-1-YL) BUTOXY]-1H-QUINOLIN-2-ONE OR SALT THEREOF | |
| CN104606146B (en) | A kind of esomeprazole enteric capsules preparation and preparation method thereof | |
| CN104940156B (en) | Epalrestat enteric-coated sustained-release tablet and preparation method thereof | |
| WO2009101940A1 (en) | Tablet having improved elution properties | |
| JP2011503017A (en) | Hydromorphone-containing sustained-release tablets | |
| CN104042586A (en) | Paroxetine enteric-coated and sustained-release tablet and preparation method thereof | |
| JP2022538214A (en) | Oral solid tablet containing Bruton's tyrosine kinase inhibitor and method for preparing same | |
| WO2006080481A1 (en) | Multiple unit oral sustained release preparation and process for production of the same | |
| JP2015500853A (en) | Immediate release multi-unit pellet system | |
| CN103784414A (en) | Esomeprazole enteric-coated tablets and preparation method thereof | |
| JP5787881B2 (en) | Enteric tablets | |
| CN101485640B (en) | Huperzine A mono-layer osmotic pump controlled release tablets | |
| CN101347413B (en) | Quetiapine sustained release tablets and method of preparing the same | |
| CN102908331A (en) | Duloxetine hydrochloride enteric capsules and preparation method thereof | |
| SI22849A (en) | Ropinirole preparation | |
| WO2024124785A1 (en) | Clopidogrel bisulfate and aspirin tablet, preparation method therefor, and use thereof | |
| CN101081217A (en) | Slow-release small pill prparation containing huperzine A and method for making same | |
| CN103405395B (en) | Sodium picosulfate enteric-coated tablet and preparation method thereof | |
| CN104523642A (en) | Metoprolol sustained-release tablet and preparation method thereof | |
| CN105816436B (en) | A kind of Pantoprazole enteric-coated micro-pill, Pantoprazole enteric slow-release tablet agent and preparation method thereof | |
| CN106983729A (en) | Pramipexole sustained release tablets and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140917 |